ReviewJCO precision oncology2022

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline

Joanne Lundy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.